Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00201695 · ClinicalTrials.gov registry record · Phase 2
Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
A Phase 2 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00201695 is a Phase 2 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 12 participants.
The verdict
NCT00201695, a Phase 2 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will assess the ability of Doxorubicin, Vincristine and Dexamethasone plus arsenic trioxide to achieve an overall response rate of greater than 60%.
Interventions
- DRUG Dexamethasone
- DRUG Vincristine
- DRUG Arsenic Trioxide
- DRUG Doxil®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-07 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00201695
The ClinicalTrials.gov registry entry for NCT00201695 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT00201695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00201695 about?
NCT00201695 is a clinical study titled "Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma". This study will assess the ability of Doxorubicin, Vincristine and Dexamethasone plus arsenic trioxide to achieve an overall response rate of greater than 60%.
What is the current status of trial NCT00201695?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2004-07. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00201695?
The interventions under investigation include: Dexamethasone (DRUG), Vincristine (DRUG), Arsenic Trioxide (DRUG), Doxil® (DRUG).
Who is sponsoring clinical trial NCT00201695?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.